U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07193147) titled 'Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment' on Sept. 18.
Brief Summary: This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.
Study Start Date: Oct. 13
Study Type: INTERVENTIONAL
Condition:
Diabetes
Intervention:
DRUG: GZR4
GZR4 s.c., single-dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gan & Lee Pharmaceuticals.
Published by HT Digital Content Services with permission from Health Daily Digest....